Fredun Pharmaceuticals Ltd
₹ 1,625
-2.58%
18 Dec
- close price
About
Incorporated in 1987, Fredun Pharmaceuticals
Ltd manufactures & exports healthcare and pharmaceuticals products[1]
Key Points
- Market Cap ₹ 767 Cr.
- Current Price ₹ 1,625
- High / Low ₹ 1,999 / 635
- Stock P/E 26.6
- Book Value ₹ 334
- Dividend Yield 0.04 %
- ROCE 18.9 %
- ROE 15.8 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 61.4% CAGR over last 5 years
- Company's median sales growth is 26.8% of last 10 years
Cons
- Debtor days have increased from 85.2 to 142 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21 | 25 | 42 | 57 | 60 | 97 | 113 | 134 | 222 | 275 | 348 | 456 | 535 | |
| 20 | 24 | 38 | 53 | 54 | 87 | 104 | 126 | 208 | 247 | 310 | 401 | 465 | |
| Operating Profit | 1 | 2 | 4 | 3 | 6 | 10 | 8 | 8 | 14 | 28 | 38 | 55 | 70 |
| OPM % | 7% | 7% | 9% | 6% | 10% | 11% | 7% | 6% | 6% | 10% | 11% | 12% | 13% |
| 0 | 0 | 1 | 2 | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 0 | 0 | |
| Interest | 1 | 1 | 2 | 2 | 2 | 3 | 4 | 4 | 5 | 9 | 14 | 22 | 27 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 4 | 4 | 5 |
| Profit before tax | 0 | 1 | 2 | 2 | 3 | 6 | 2 | 3 | 9 | 18 | 21 | 28 | 37 |
| Tax % | 47% | 52% | 42% | 36% | 34% | 28% | 24% | 37% | 26% | 38% | 27% | 26% | |
| 0 | 0 | 1 | 1 | 2 | 4 | 2 | 2 | 6 | 11 | 16 | 21 | 29 | |
| EPS in Rs | 1.02 | 1.11 | 4.55 | 6.08 | 5.11 | 11.18 | 4.76 | 5.04 | 14.30 | 23.85 | 33.22 | 44.07 | 61.21 |
| Dividend Payout % | 0% | 0% | 13% | 10% | 12% | 6% | 14% | 14% | 5% | 3% | 2% | 2% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 34% |
| 5 Years: | 32% |
| 3 Years: | 27% |
| TTM: | 37% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 54% |
| 5 Years: | 61% |
| 3 Years: | 49% |
| TTM: | 63% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 37% |
| 3 Years: | 10% |
| 1 Year: | 115% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 13% |
| 3 Years: | 15% |
| Last Year: | 16% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 |
| Reserves | 0 | 0 | 1 | 2 | 19 | 35 | 37 | 39 | 64 | 92 | 117 | 137 | 153 |
| 7 | 9 | 16 | 21 | 10 | 19 | 35 | 40 | 53 | 87 | 106 | 166 | 171 | |
| 8 | 11 | 24 | 30 | 47 | 47 | 65 | 79 | 66 | 74 | 81 | 179 | 136 | |
| Total Liabilities | 18 | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 | 487 | 464 |
| 7 | 8 | 15 | 16 | 16 | 31 | 31 | 30 | 32 | 39 | 47 | 53 | 65 | |
| CWIP | 0 | 1 | 0 | 4 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 |
| 11 | 14 | 29 | 36 | 52 | 74 | 110 | 131 | 155 | 218 | 260 | 433 | 397 | |
| Total Assets | 18 | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 | 487 | 464 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1 | 2 | 3 | 4 | 17 | 1 | -11 | 0 | -2 | -14 | -0 | -29 | |
| -2 | -3 | -6 | -7 | -8 | -5 | -1 | -1 | -4 | -9 | -8 | -6 | |
| 2 | 1 | 3 | 3 | -8 | 4 | 14 | -1 | 7 | 25 | 6 | 38 | |
| Net Cash Flow | -0 | 0 | 1 | -1 | 1 | 0 | 2 | -2 | 1 | 1 | -2 | 3 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 59 | 75 | 98 | 131 | 94 | 67 | 126 | 112 | 148 | 46 | 68 | 142 |
| Inventory Days | 107 | 102 | 140 | 68 | 170 | 249 | 227 | 242 | 96 | 264 | 246 | 265 |
| Days Payable | 152 | 167 | 221 | 224 | 360 | 205 | 208 | 215 | 101 | 104 | 88 | 160 |
| Cash Conversion Cycle | 14 | 11 | 17 | -24 | -96 | 110 | 145 | 139 | 144 | 205 | 225 | 247 |
| Working Capital Days | -44 | -54 | -44 | -39 | 42 | 66 | 65 | 116 | 126 | 97 | 92 | 76 |
| ROCE % | 14% | 14% | 25% | 18% | 16% | 21% | 10% | 10% | 13% | 18% | 17% | 19% |
Documents
Announcements
-
Corrigendum Through General Announcement Regarding Disclosure Of Pre-Preferential Shareholding Of Proposed Allottees, Ultimate Beneficial Owners (Ubos), Revised Issue Size Of Proposed Preferential Allotment, Revised List Of Allottees And Bifurcation And Brief Description Of The Object Of The Issue And Post Shareholding Pattern In Connection With The Extra-Ordinary General Meeting (EGM) Held On October 22, 2025
1h - Corrigendum: Revised preferential issue ₹149.49 crore; allottee/UBO list and post-issue shareholding (EGM Oct 22, 2025).
-
Corrigendum Through General Announcement Regarding Disclosure Of Pre-Preferential Shareholding Of Proposed Allottees, Ultimate Beneficial Owners (Ubos), Revised Issue Size Of Proposed Preferential Allotment, Revised List Of Allottees And Bifurcation And Brief Description Of The Object Of The Issue In Connection With The Extra-Ordinary General Meeting (EGM) Held On October 22, 2025.
7h - Corrigendum Dec 18, 2025: Preferential issue — 6,44,360 shares; 5,51,600 warrants; proposed proceeds ~₹153.25 Crore.
-
Intimation Of Outcome Of Analysts/Investors Meeting Under The SEBI (Listing Obligations And Disclosures Requirements) Regulation, 2015
24h - 16 Dec 2025 analysts/investors call 'Beyond the Numbers - Value Discovery Summit-2025'; no UPSI shared
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
11 Dec - Of Schedule of 'Value Discovery Summit', under the SEBI (Listing Obligations and Disclosure Requirement), Regulation 2015.
-
Corrigendum Through General Announcement Regarding Disclosure Of Ultimate Beneficial Owners (Ubos), Pre -Preferential Shareholding Of Proposed Allottees And Bifurcation And Brief Description Of The Object In Connection With The Extra-Ordinary General Meeting (EGM) Held On October 22, 2025.
29 Nov - Corrigendum discloses UBOs, pre-preferential holdings, and ₹153.25 Cr use of proceeds after Oct 22, 2025 EGM.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2010
from bse
Concalls
-
Nov 2025TranscriptPPTREC
-
Aug 2025TranscriptPPTREC
-
Jun 2025TranscriptAI SummaryPPT
-
Jun 2025TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Jun 2019TranscriptAI SummaryPPT
Business Overview:[1]
The company, a subsidiary of the Fredun Group, manufactures pharmaceutical and allopathic formulations including tablets, syrups, capsules, and ointments across therapeutic areas like anti-diabetics, anti-retrovirals, and anti-hypertensives. It has also expanded into dietary and herbal supplements, nutraceuticals, diagnostic kits, and animal healthcare products through group entities Fredun Healthcare Pvt. Ltd. and Fredna Enterprises.